Clinical and demographic characteristics of patients with advanced HR+/HER2- breast cancer receiving ribociclib combined with endocrine therapy or combination chemotherapy in Russian clinical practice: second interim analysis of the ValerEE study dat

This article presents the results of the second interim analysis of data from the ValerEE study. The analysis examined a population of patients with advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer receiving either ribociclib combined with endocrine therapy (ET) or combination chemotherapy (CT) as first-line treatment in a real-world clinical setting in Russia. The study enrolled 100 % of the planned number of participants (N=333; 188 in the ribociclib plus ET group and 145 in the combination CT group). The groups were balanced regarding age (mean: 59.2 years), body mass index (mean: 27.7), menopausal status (75.7 % postmenopausal), and gender. Statistically significant differences between the groups were identified: the ribociclib plus ET group showed a higher proportion of patients with an ECOG performance status of 0 (20.7 % vs. 9.7 %, p=0.0208) and higher mean expression levels of estrogen receptors (7.4 vs. 6.9, p<0.001) and progesterone receptors (6.2 vs. 4.9, p<0.001); HER2-low status was also more frequent (38.8 % vs. 31.1 %, p=0.0344). Metastatic disease, including locoregional metastases, was more common in the chemotherapy group. The findings indicate that, in standard clinical practice in the Russian Federation, the selection of patients with HR+/HER2- recurrent/metastatic breast cancer for first-line therapy is based on clinical and biological characteristics. These differences must be taken into account when interpreting the comparative efficacy of these approaches.

Authors

Institutions

Publication Details

Journal
Medical alphabet
Published
2026-11-17
DOI
https://doi.org/10.33667/2078-5631-2026-27-43-54
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical and demographic characteristics of patients with advanced HR+/HER2- breast cancer receiving ribociclib combined with endocrine therapy or combination chemotherapy in Russian clinical practice: second interim analysis of the ValerEE study dat

T.V. Vinogradova, Гармарник Татьяна Валерьевна, Liubov Yu Vladimirova, Елена Владимировна Артамонова et al.
Medical alphabet
Advanced Breast Cancer Therapies
article

Clinical and demographic characteristics of patients with advanced HR+/HER2- breast cancer receiving ribociclib combined with endocrine therapy or combination chemotherapy in Russian clinical practice: second interim analysis of the ValerEE study dat

T.V. Vinogradova, Гармарник Татьяна Валерьевна, Liubov Yu Vladimirova, Елена Владимировна Артамонова, Е. V. Lymar, Роман Сергеевич Жихорев, Дергунов Александр Сергеевич, Violetta Reznikov, S.B. Belonogov, E. V. Semenov, Lyudmila Zhukova, Воронкова Лия Михайловна, Надежда Витальевна Леушина, O.V. Mironov
article en

Abstract

This article presents the results of the second interim analysis of data from the ValerEE study. The analysis examined a population of patients with advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer receiving either ribociclib combined with endocrine therapy (ET) or combination chemotherapy (CT) as first-line treatment in a real-world clinical setting in Russia. The study enrolled 100 % of the planned number of participants (N=333; 188 in the ribociclib plus ET group and 145 in the combination CT group). The groups were balanced regarding age (mean: 59.2 years), body mass index (mean: 27.7), menopausal status (75.7 % postmenopausal), and gender. Statistically significant differences between the groups were identified: the ribociclib plus ET group showed a higher proportion of patients with an ECOG performance status of 0 (20.7 % vs. 9.7 %, p=0.0208) and higher mean expression levels of estrogen receptors (7.4 vs. 6.9, p<0.001) and progesterone receptors (6.2 vs. 4.9, p<0.001); HER2-low status was also more frequent (38.8 % vs. 31.1 %, p=0.0344). Metastatic disease, including locoregional metastases, was more common in the chemotherapy group. The findings indicate that, in standard clinical practice in the Russian Federation, the selection of patients with HR+/HER2- recurrent/metastatic breast cancer for first-line therapy is based on clinical and biological characteristics. These differences must be taken into account when interpreting the comparative efficacy of these approaches.

Medical alphabet(27)
Pirogov Russian National Research Medical University (RU), Moscow Clinical Scientific Center (RU), Krasnoyarsk State Medical University (RU), Russian Cancer Research Center NN Blokhin (RU), Clinical Hospital No. 8 (RU), Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky (RU), Ministry of Health of the Russian Federation (RU), Novartis (United States) (US), Republican Oncological Clinical Dispensary (RU), Tyumen Regional Oncological Dispensary (RU), State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU), Moscow City Oncology Hospital №62 (RU)
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon